Johnson & Johnson (JNJ)
Technical, fundamental, and sentiment analysis with recent related videos.
JNJ rates Neutral overall. The fundamental read is neutral: the company passes 3 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 5.46); revenue is declining about 0.0% per year; net income is growing about 42.2% per year. The technical picture is bullish: price is 8.2% above the 200-day moving average; 0.5% below the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 74/100), based on 8 news articles and 2 qualified videos from recent coverage.
Revenue 3-year avg -0.0%. Net income 3-year avg +42.2%.
Price vs 20DMA +1.8%. RSI 53.07. Bollinger state: Inside Bands.
Composite score 74/100 from the AI judge, based on 8 news items, 0 television segments, and 2 videos.
Latest Market Read
Johnson & Johnson’s three badges split the picture. The Fundamental badge is Neutral because revenue has averaged -0.0 percent per year while net income averaged 42.2 percent per year, so gains in profit offset a weak top line. The Technical badge is Bullish: price sits about 1.8 percent above its 20-day moving average and inside the Bollinger Bands, with the Relative Strength Index (RSI), a momentum reading, at 53.1. Sentiment is Bullish with a 74 composite. Overall Neutral: strong technical and bullish sentiment conflict with a muted revenue trend, so the combined rating does not flip.
Recent news: Global Database of Events, Language, and Tone (GDELT) and Internet Archive TV coverage focused on multiple trial readouts: Phase 3 PROTEUS showed apalutamide plus ADT improved event‑free survival, Phase 1b/2 Rybrevant Faspro cohorts reported about 77 percent response rates with some complete responses, and Biocon expanded biosimilar distribution under Janssen. Coverage also noted a collapsed Smith & Nephew takeover that introduced M&A uncertainty, while recent videos highlighted J&J earnings beats and raised guidance.